Clinical Trial Update: Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Agaricus blazei Murill (ABM) in inflammatory bowel disease has completed; no efficacy or safety results are provided in the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Agaricus blazei Murill (ABM) (Agaricus blazei Murill)

Snippet

Sponsor: Ullevaal University Hospital | Conditions: Inflammatory Bowel Disease | Phase 2 | Status: COMPLETED